Pronunciation: [kˈe͡ɪpɹəmˌab] (IPA) 
"Capromab" is a coined word that is often used in medical settings to refer to a particular monoclonal antibody. Phonetically, it is pronounced /kəˈproʊmæb/. The spelling of this word can be broken down into its syllables: "cap" + "ro" + "mab". The "ca" and "pro" sounds are pronounced as they are spelled, while the "mab" portion is likely derived from the term monoclonal antibody, with the "m" and "ab" sounds blended together.
Capromab is a term used in medicine and pharmacology, specifically in the field of diagnostic imaging and cancer treatment. It refers to an antibody-based agent known as Capromab pendetide.
Capromab pendetide is a radiopharmaceutical drug developed for the diagnosis and staging of prostate cancer. It is composed of a monoclonal antibody, called Capromab, which specifically targets an antigen known as Prostate-Specific Membrane Antigen (PSMA) found on the surface of prostate cancer cells. The antibody is chemically modified and labeled with a radioactive isotope, Technetium-99m (Tc-99m), allowing its detection and imaging via Single Photon Emission Computed Tomography (SPECT).
Upon administration, Capromab pendetide binds to PSMA on prostate cancer cells, allowing the visualization and localization of tumors or metastases in the prostate gland, lymph nodes, or other affected areas. This helps physicians to accurately stage the disease and determine the extent of cancer spread.
In addition to diagnostic applications, Capromab pendetide has also been investigated as a potential therapeutic agent for the treatment of prostate cancer. It may be used in combination with other cancer treatments, such as radiotherapy or chemotherapy, to enhance their effectiveness by targeting cancer cells specifically.
Overall, Capromab pendetide, or Capromab, is an antibody-based radiopharmaceutical that plays a crucial role in the diagnosis and management of prostate cancer, providing clinicians with valuable imaging information for disease staging and guiding therapeutic interventions.
